Contraindication with Depression Med Prompts Labeling Update for Several HIV Drugs
The Food and Drug Administration (FDA) announced that the following antiretroviral drug labels have been updated to include Latuda (lurasidone; Sunovion) to the Contraindications section due to the potential for serious and/or life-threatening reactions:
- Aptivus (tipranavir)
- Crixivan (indinavir)
- Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide)
- Invirase (saquinavir)
- Kaletra (lopinavir, ritonavir)
- Lexiva (fosamprenavir) - lurasidone is contraindicated if Lexiva is coadministered with ritonavir
- Norvir (ritonavir)
- Prezista (darunavir)
- Reyataz (atazanavir) - lurasidone is contraindicated if Reyataz is coadministered with ritonavir
- Stribild (elvitegravir, cobicistat, tenofovir disoproxil fumarate)
- Viracept (nelfinavir)
Latuda, an atypical antipsychotic, is indicated to treat adults with major depressive episodes associated with bipolar I disorder as monotherapy and as adjunctive therapy with lithium or valproate; and to treat schizophrenia.
The labels for Evotaz (atazanavir, cobicistat) and Prezcobix (darunavir, cobicistat) already include lurasidone as a contraindicated agent in the Contraindications section. The aforementioned antiretrovirals are indicated to treat HIV-1 infection.
For more information call (888) 463-6332 or visit FDA.gov.